To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Pneumococcal polysaccharide vaccine
Pneumococcal polysaccharide vaccine (PPV), also known as Pneumovax, is a vaccine used to prevent Streptococcus pneumoniae (pneumococcus) infections such as pneumonia and septicaemia. PPV is not the same vaccination as the pneumococcal conjugate vaccine (PCV) that is routinely administered to infants in the US, Canada, and the UK. See further under Children, below.
Additional recommended knowledge
In the United Kingdom, PPV is recommended (as a part of routine vaccination schedules) for those over the age of 65, and also for both children and adults in special risk categories:
The 23-valent vaccine (e.g., Pneumovax II) is only appropriate for adults and usually should only be administered once, as subsequent re-injection risks severe local reactions. The exception is where immunity may be lost at a faster rate than normal (e.g. patients with asplenia or nephrotic syndrome) when repeated re-vaccination every 5-10 years is recommended.
Children under the age of two years fail to mount an adequate response to the 23-valent adult vaccine, and instead a 7-valent Pneumococcal Conjugated Vaccine (PCV) (e.g., Prevnar) must be used. Whilst this covers only seven strains out of more than ninety strains, these seven strains cause 80% to 90% of cases of severe pneumococcal disease, and it is considered to be nearly 100% effective against these strains.
Notes and references
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pneumococcal_polysaccharide_vaccine". A list of authors is available in Wikipedia.|